7 terminated, 4 completed, 2 not yet recruiting, 2 recruiting. 17 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Terminated 7, Completed 4, Not yet recruiting 2, Recruiting 2, Withdrawn 2 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Metastatic Disease: new trials by email Literature Review of Metastatic Disease trials Research Report on Metastatic Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma mFOLFIRINOX versus FOLFOX chemotherapy - Small-bowel Adenocarcinoma, Metastatic Disease | Phase 2 | Not yet recruiting | Annika Kurreck | 86 | 2026-10-01 | 2026-09-28 |
| Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck Zanzalintinib - Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence | Phase 2 | Not yet recruiting | UNICANCER | 51 | 2026-10-01 | 2026-07-06 |
| Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy) - Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-06-04 |
| OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites stereotactic radiation therapy in ablative doses to each metastatic site - Metastatic Disease | Phase 2 | Recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 50 | 2025-02-07 | 2025-03-04 |
| IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study Darleukin, Radiation - NSCLC Stage IV, Metastatic Disease | Phase 2 | Terminated | Maastricht University Medical Center | 88 | 2019-04-04 | 2025-01-30 |
| Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Melanoma vaccine modified to express HLA A2/4-1BB ligand - High Risk HLA-A2+ Melanoma, Metastatic Disease | Phase 2 / Phase 3 | Withdrawn | Hadassah Medical Organization | 2017-03-01 | 2025-10-02 | |
| Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) Nintedanib, Fluorouracil, Leucovorin - Esophagogastric Adenocarcinoma, Metastatic Disease | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2016-12-01 | 2017-05-09 | |
| Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab Regorafenib - Colorectal Neoplasms, Metastatic Disease | Phase 2 | Terminated | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 15 | 2014-06-01 | 2017-08-01 |
| Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer Regorafenib - Colorectal Neoplasms, Metastatic Disease | Phase 2 | Completed | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 46 | 2013-06-01 | 2017-08-01 |
| Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic Arm A chemotherapy, arm B chemotherapy - Adenocarcinoma of Colon, Adenocarcinoma of Rectum | Phase 2 | Completed | Centro Nacional de Investigaciones Oncologicas CARLOS III | 29 | 2012-11-01 | 2015-10-09 |
| Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy AUY922 - Adenocarcinoma of the Pancreas, Metastatic Disease | Phase 2 | Terminated | University Health Network, Toronto | 15 | 2012-01-01 | 2019-02-15 |
| Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Itraconazole - Prostate Cancer, Prostatic Neoplasms | Phase 2 | Terminated | Stanford University | 4 | 2010-09-01 | 2017-04-11 |
| Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Temsirolimus, Casodex (bicalutamide) - Prostate Cancer, Prostatic Neoplasms | Phase 1 / Phase 2 | Terminated | Sandy Srinivas | 5 | 2009-10-01 | 2014-10-13 |
| Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Nilotinib, Nilotinib with Imatinib - GIST, Metastatic Disease | Phase 2 | Terminated | Fox Chase Cancer Center | 5 | 2009-02-01 | 2017-03-15 |
| Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal Sorafenib - Renal Cell Carcinoma, Metastatic Disease | Phase 2 | Completed | University Health Network, Toronto | 19 | 2007-05-01 | 2015-12-09 |
| Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) Nexavar (Sorafenib), IL-2 - Metastatic Disease, Renal Cell Carcinoma | Phase 2 | Completed | Italian Trial in Medical Oncology | 90 | 2006-11-01 | 2009-02-26 |
| Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen Tamoxifen - Breast Cancer, Metastatic Disease | Phase 2 | Terminated | National Cancer Center, Korea | 21 | 2006-06-01 | 2010-02-10 |
Neoplasm Metastasis (17) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Melanoma (1) · Rectal Neoplasms (1) · Recurrence (1)
Neoplasms (17) · Neoplastic Processes (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Neoplasms by Site (12) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Colonic Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3)
Sorafenib (3) · Fluorouracil (2) · Oxaliplatin (2) · regorafenib (2) · 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide (1) · Capecitabine (1) · Cetuximab (1) · Cisplatin (1) · Cyclophosphamide (1) · Dasatinib (1) · Docetaxel (1) · Doxorubicin (1) · Erlotinib Hydrochloride (1) · Etoposide (1) · Gemcitabine (1)
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (2) · University Health Network, Toronto (2) · Annika Kurreck (1) · Beijing Biotech (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fox Chase Cancer Center (1) · Hadassah Medical Organization (1) · Italian Trial in Medical Oncology (1) · Maastricht University Medical Center (1) · National Cancer Center, Korea (1) · National Medical Research Radiological Centre of the Ministry of Health of Russia (1) · Sandy Srinivas (1) · Stanford University (1) · UNICANCER (1)
Spain (3) · United States (3) · Canada (2) · France (2) · Germany (2) · Italy (2) · Belgium (1) · China (1) · Netherlands (1) · Russia (1) · South Korea (1) · United Kingdom (1)
A. Ardizzoia, MD (1) · A. Bertolini, MD (1) · Alfredo Carrato, MD-PhD (1) · Andrey Kaprin, PhD (1) · Annika Kurreck, PD Dr. (1) · Antonio Finelli, MD,MSc,FRCSC (1) · C. Porta, MD (1) · D. Amadori, MD (1) · Dr. Sandy Srinivas (1) · E. Aitini, MD (1) · Enrique Grande, MD (1) · G. Conti, MD (1) · G. Fasola, MD (1)
PMID 24063860, PMID 30120161, PMID 32539805, PMID 33688020, PMID 37146227
2014 (1), 2016 (1)